78 related articles for article (PubMed ID: 26896828)
1. Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody.
Galluppi GR; Wisniacki N; Stebbins C
Br J Clin Pharmacol; 2016 Jul; 82(1):118-28. PubMed ID: 26896828
[TBL] [Abstract][Full Text] [Related]
2. Phase I, Randomized, Placebo-Controlled, Dose-Escalation Study of GB223, a Fully-Humanized Monoclonal Antibody to RANKL, in Healthy Chinese Adults.
Li C; Liu H; Liao Y; Zhu Y; Tian J; Wang X; Hu Z; Zhan Y; Li X; Liang X; He J; Li Y; Shang D; Zheng Q; Wang T; Song H; Fang Y
BioDrugs; 2023 Sep; 37(5):721-735. PubMed ID: 37278972
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
[TBL] [Abstract][Full Text] [Related]
4. Comparability of Elezanumab Safety, Tolerability, and Pharmacokinetics in Healthy Japanese, Chinese, and White Participants.
Kalluri HV; Rosebraugh MR; Boehm N; Locke C; Ziemann A; Xiong H
Clin Pharmacol Drug Dev; 2024 Feb; 13(2):180-189. PubMed ID: 38191982
[TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of tumour necrosis factor-like weak inducer of apoptosis in children with autism spectrum disorder.
Artık A; Öztelcan Gündüz B; Mızrak S; Işık Ü
Int J Dev Disabil; 2023; 69(4):611-616. PubMed ID: 37346259
[No Abstract] [Full Text] [Related]
6. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia.
Sun X; Liu W; Luo B; Ma D; Kalluru H; Zhou Y; Li J; Peng A; Liu Y; Tong X; Sun L; Teeter J; Raje S; Yang R
Haemophilia; 2023 Jul; 29(4):1155-1159. PubMed ID: 37339017
[No Abstract] [Full Text] [Related]
7. Role of serum levels of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) in predicting severity of acute appendicitis.
Zülfikaroğlu B; Akkurt G; Akın M; İşman FK; Yastı AÇ; Özmen MM
Turk J Surg; 2023 Jun; 39(2):121-127. PubMed ID: 38026909
[TBL] [Abstract][Full Text] [Related]
8. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Lupus; 2016 Jun; 25(7):699-709. PubMed ID: 26936891
[TBL] [Abstract][Full Text] [Related]
9. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
van Vollenhoven RF; Petri M; Wallace DJ; Roth DA; Molta CT; Hammer AE; Tang Y; Thompson A
Arthritis Rheumatol; 2016 Sep; 68(9):2184-92. PubMed ID: 26992106
[TBL] [Abstract][Full Text] [Related]
10. Urinary dedifferentiated podocytes as a non-invasive biomarker of lupus nephritis.
Perez-Hernandez J; Olivares MD; Forner MJ; Chaves FJ; Cortes R; Redon J
Nephrol Dial Transplant; 2016 May; 31(5):780-9. PubMed ID: 26932688
[TBL] [Abstract][Full Text] [Related]
11. Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.
Choe JY; Kim SK
Inflamm Res; 2016 Jun; 65(6):479-88. PubMed ID: 26921306
[TBL] [Abstract][Full Text] [Related]
12. Evidence for genetic association of TBX21 and IFNG with systemic lupus erythematosus in a Chinese Han population.
Leng RX; Pan HF; Liu J; Yang XK; Zhang C; Tao SS; Wang DG; Li XM; Li XP; Yang W; Ye DQ
Sci Rep; 2016 Feb; 6():22081. PubMed ID: 26916970
[TBL] [Abstract][Full Text] [Related]
13. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.
Wenzel J; van Holt N; Maier J; Vonnahme M; Bieber T; Wolf D
J Invest Dermatol; 2016 Jun; 136(6):1281-1283. PubMed ID: 26916391
[No Abstract] [Full Text] [Related]
14. Rituximab in lupus nephritis: A non-systematic review.
Zurita Gavilanes L; Costa Valarezo A
Reumatol Clin; 2016; 12(4):210-5. PubMed ID: 26906063
[TBL] [Abstract][Full Text] [Related]
15. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
[TBL] [Abstract][Full Text] [Related]
16. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
[TBL] [Abstract][Full Text] [Related]
18. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
19. [Combination of tacrolimus and MMF for treatment of proliferative lupus nephritis].
Weiner SM
Z Rheumatol; 2016 Jun; 75(5):517. PubMed ID: 27259912
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
